uniQure N.V.
AMT-130
Huntington’s disease
Countdown
86days
FDA decision · ~ Sep 30, 2026 estimated
What's at stake
The FDA's approval decision on AMT-130 for Huntington’s disease is due ~ Sep 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 11h ago
“The Company intends to submit the BLA in third quarter of 2026.”